Rinvoq and Verapamil Extended Release Tablets
Determining the interaction of Rinvoq and Verapamil Extended Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased. MANAGEMENT: Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. References "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Professional:MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.
MANAGEMENT: Caution is recommended if upadacitinib is used with moderate CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy.
- "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Generic Name: verapamil
Brand name: Calan, Isoptin SR, Verelan, Isoptin, Calan SR, Isoptin IV, Covera-HS, Verelan PM
Synonyms: Verapamil
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Rinvoq-Verapamil Hydrochloride
- Rinvoq-Verapamil Hydrochloride PM
- Rinvoq-Verapamil Immediate-Release Tablets
- Rinvoq-Verapamil Injection
- Rinvoq-Verapamil Intravenous
- Rinvoq-Verapamil Long-Acting Capsules
- Verapamil Extended Release Tablets-Riociguat
- Verapamil Extended Release Tablets-Riomet
- Verapamil Extended Release Tablets-Riomet Oral Suspension
- Verapamil Extended Release Tablets-Risankizumab
- Verapamil Extended Release Tablets-Risankizumab-rzaa topical
- Verapamil Extended Release Tablets-Risedronate